The global hypertrophic cardiomyopathy (HCM) therapeutics market is estimated to grow at a CAGR of nearly 1.5% during the forecast period. With the increasing prevalence of cardiomyopathy, some companies are focusing on launching new HCM drugs with minimal side-effects, and higher safety and reliability. The Companies whose HCM medications are in clinical phases include Novartis International AG and MyoKardia, Inc. Novartis study title is “Efficacy of Oral Sacubitril/Valsartan Adult Patients with Non-obstructive Hypertrophic Cardiomyopathy” and the drug name is LCZ696 (Entresto) which is in Phase II study. This study aims to validate the safety and tolerability of LCZ696 and it can improve the exercise capacity in patients with non-obstructive HCM during the course treatment of 50 weeks. Doses of LCZ696 include 50mg, 100mg and 200mg. As a pharmacological agent, Sacubitril / Valsartan shall be studied which intends to validate the effects of this medication on physiology and cardiac morphology in HCM patients.
A full report of Hypertrophic Cardiomyopathy (HCM) Therapeutics Market is available at: https://www.omrglobal.com/industry-reports/hypertrophic-cardiomyopathy-hcm-therapeutics-market
In January 2019, MyoKardia and Sanofi ends four-year drug collaboration for the treatment of heart disease. This agreement was intended for combined development of small-molecule therapeutics, targeting genetic mutations that are associated with certain heart diseases. With the end of this agreement, MyoKardia has global rights for all clinical programs in its portfolio, which include major clinical-stage candidates, MYK-491 (Phase IIa) and mavacamten (Phase III). With the regaining of the global rights, MyoKardia allows capturing the entire value of the data being produced in the upcoming 12-24 months coupled with the efficient registration of mavacamten in obstructive HCM and MYK-491 in patients with dilated cardiomyopathy. The control in the whole portfolio will enable the MyoKardia to advance every treatment candidate along with its precision medicine approach.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/hypertrophic-cardiomyopathy-hcm-therapeutics-market
In July 2019, MyoKardia declared the re-acquisition of the US royalty rights to MYK-224 and mavacamten from Sanofi S.A. MyoKardia is paying $50 million upfront to Sanofi as consideration for the buyback of the US royalty rights to HCM programs, with an additional $30 million payable by June 2020. Sanofi was eligible for tiered royalties, varying from 5% to 10%, on the US sales of MYK-224 and mavacamten in HCM or any further indications (as per the former partnership agreement with Sanofi). This reacquisition is an essential strategic step for MyoKardia as the company is looking forward to potential registration and commercial launch of mavacamten in the US and the imminent innovation of MYK-224 into clinical studies. These medications may create hope for patients seeking potential treatment for the condition that will likely offer an opportunity for the global HCM therapeutics market.
Global HCM Therapeutics Market- Segmentation
By Drug Class
- Beta Adrenergic Blocking Agents
- Anticoagulants
- Antiarrhythmic Agents
- Calcium Channel Blockers
- Others
